263 related articles for article (PubMed ID: 34907086)
21. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
[TBL] [Abstract][Full Text] [Related]
23. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.
Ou SI; Zhu VW
Lung Cancer; 2019 Apr; 130():201-207. PubMed ID: 30885345
[TBL] [Abstract][Full Text] [Related]
24. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
25. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
[TBL] [Abstract][Full Text] [Related]
26. MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Tyler LC; Le AT; Chen N; Nijmeh H; Bao L; Wilson TR; Chen D; Simmons B; Turner KM; Perusse D; Kasibhatla S; Christiansen J; Dudek AZ; Doebele RC
Thorac Cancer; 2022 Nov; 13(21):3032-3041. PubMed ID: 36101520
[TBL] [Abstract][Full Text] [Related]
27. Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings.
Dong W; Zhuge J; Yu P; Liu K; Yang M; Wang H
Medicine (Baltimore); 2023 Dec; 102(51):e36591. PubMed ID: 38134118
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
29. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
30. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
[TBL] [Abstract][Full Text] [Related]
31. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
32. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
[TBL] [Abstract][Full Text] [Related]
33. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
[TBL] [Abstract][Full Text] [Related]
34. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
Cai L; Duan J; Qian L; Wang Z; Wang S; Li S; Wang C; Zhao J; Zhang X; Bai H; Wang J
Front Immunol; 2020; 11():527750. PubMed ID: 33324391
[TBL] [Abstract][Full Text] [Related]
35. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
Wang Y; Chen Z; Han X; Li J; Guo H; Shi J
Oncologist; 2021 Mar; 26(3):178-181. PubMed ID: 33000474
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1
Liu S; Huang C; Huang C; Huang Y; Yu Y; Wu G; Guo F; Jiang Y; Wan S; Zhu Z; Tian Y; Zhu J; Zhang J
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2227779. PubMed ID: 37349867
[TBL] [Abstract][Full Text] [Related]
37. 3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer.
Gong B; Oh-Hara T; Fujita N; Katayama R
Biochem Biophys Res Commun; 2018 Jun; 501(2):527-533. PubMed ID: 29738763
[TBL] [Abstract][Full Text] [Related]
38. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
[TBL] [Abstract][Full Text] [Related]
39. Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression.
Peters TL; Chen N; Tyler LC; Le AT; Dimou A; Doebele RC
Thorac Cancer; 2023 Nov; 14(33):3259-3265. PubMed ID: 37727007
[TBL] [Abstract][Full Text] [Related]
40. Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.
Facchinetti F; Friboulet L
Lung Cancer (Auckl); 2019; 10():87-94. PubMed ID: 31572036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]